Condition
Sporotrichosis
Total Trials
5
Recruiting
1
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (2)
Trial Status
Completed4
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06300138Not ApplicableRecruitingPrimary
Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis
NCT06523998CompletedPrimary
A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica.
NCT00004811Phase 1Completed
Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis
NCT00004938Phase 2CompletedPrimary
Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis
NCT00004808Phase 2Completed
Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis
Showing all 5 trials